|
|
Product Details:
Payment & Shipping Terms:
|
Package: | 30 Tests/box | Specificity: | 100% |
---|---|---|---|
Sensitivity: | 100% |
HIV-1/2 Gold Rapid Screen Test WB/S/P
Package:40 tests per box
INTENDED USE
The HIV-1/2 Rapid Screen Test (RST) is a qualitative test for the detection of antibodies to Human Immunodeficiency Virus type 1 and 2(HIV-1/2) in human serum/plasma and whole blood. It is considered as an initial screening test for HIV-1/2 antibodies. All positive specimens must be confirmed with Western Blot or other qualified EIA.
PRECAUTION
1.For in vitro diagnostic uses only.
2.All patient samples should be treated as if capable of transmitting diseases.
3.Do not use test kit beyond expiration date.
4.Icteric, lipemic, hemolysed, heat treated and contaminated sera may cause erroneous results.
SUMMARY AND EXPLANATION OF THE TEST
It has been shown that the acquired immunodeficiency syndrome (AIDS) is caused by viruses transmitted by sexual contact, transfusion, use of contaminated blood products and sharing contaminated needles. HIV-1 and HIV-2 viruses have been isolated from patients with AIDS and AIDS-related complex (ARC), high-risk persons for AIDS. HIV-1 and HIV-2 viruses delete T helper cells, a subpopulation of T cells for body defense, thus causing AIDS patients susceptible to opportunistic infections and developing malignant tumors. The incidence of specific antibodies to HIV-1/2 is high in AIDS, ARC and persons with high risk for AIDS. The HIV-1/2 Rapid Screen Test is designed to detect antibodies to HIV-1/2 in AIDS patients, ARC or high risk persons and identify any potential donors carrying these antibodies in serum specimens.
PRINCIPLE
HIV-1/2 RST is a chromatographic immunoassay (CIA) for the detection of antibodies to HIV-1/2 in human serum/plasma and whole blood. HIV-1/2 specific antigens are precoated onto membrane as a capture reagent on the test region. During the test, specimen is allowed to react with the colloidal gold particles, which have been labeled with HIV-1/2 specific antigens. Antibodies to HIV-1/2, if present, a red colored band will develop on the membrane in proportion to the amount of HIV-1/2 antibodies present in the specimen. Absence of this red colored band in the test region suggests a negative result. To serve as a procedural control, red colored band in the control region will always appear regardless the presence of antibodies to HIV-1/2.
MATERIALS SUPPLIED
One pouched cassette with desiccant.
Blood diluents in a dropper bottle, stored at 4-30°C.
One piece of operating instruction.
MATERIALS NOT PROVIDED BUT REQUIRED
Specimen collection container, either plastic or class.
Timer.
Disposable gloves.
SPECIMENS COLLECTION AND STORAGE
Fingers stick Specimens (Whole Blood)
Plasma
ASSAY PROCEDURE
Add 1 drop (1 drop = 35µl) of sample (whole blood/serum/plasma) into the sample well. After all samples completely absorbed, add 1 drop of diluent. Observe the result in 5-15 minutes.
QUALITY CONTROL
An internal procedural control is included in the test. red line will appears in the control region (C).
INTERPRETATION OF RESULTS
Negative: No apparent band in the test region (T), only one red band appears in the control region (C). This indicates that no HIV1/2 antibodies have been detected.
Positive: In addition to the band in the control region (C), other one red band will appear in the test region (T). This indicates that the specimen contains HIV1/2 antibodies.
Invalid: If no band appears in the control region(C), regardless of the presence or absence of line in the test region (T). It indicates a possible error in performing the test. The test should be repeated using a new device.
PERFORMANCE CHARACTERISTICS
Clinical Study
27689 HIV diagnostic samples were tested with the HIV-1/2 Rapid Screen Test. The results are summarized in the table below.
Diagnostic Sample type | Number of sample tested | HIV-1/2 Rapid Screen Test | |
negative | Positive | ||
Positive | 651 | 0 | 651 |
Negative | 27038 | 27013 | 25 |
Sensitivity=100%; Specificity=99.91%; Total accuracy=99.91%
Possible Interferences
The table below shows the results of the HIV-1/2 Rapid Screen Test on a variety of samples containing possibly interfering substances.
Sample type | Number of sample tested | HIV-1/2 Rapid Screen Test | |
negative | Positive | ||
Clinical specimens | 200 | 200 | 0 |
Pregnant woman | 200 | 200 | 0 |
Related infection(*) | 100 | 98 | 2 |
Rheumatoid Factor positive | 7 | 7 | 0 |
Multipara | 1 | 1 | 0 |
Anti-Ecol positive | 2 | 2 | 0 |
(*)The results were negative for samples containing HBsAg(15),anti-HCV(12),anti-HTLV(14),anti-VZV(4) and anti-EBV(4).1 of the 20 anti-CMV samples and 1 of the 15 anti-HAV samples were found false positive.
Precision
Intra-assay
In the study, 30 replicate assays were performed with one positive and one negative specimen. Correct negative and positive results were registered in 100% of the assays.
Inter-assay
The study involved the same specimens containing one positive and one negative. The samples were analyzed in 30 independent assays with HIV-1/2 Rapid Screen Test. originating from three different lots at different times during two months. Again, expected negative and positive results were registered in 100% of the assays.
STORAGE AND STABILITY
Store HIV-1/2 Rapid Screen Test at temperature ranges 4-30 °C in the sealed pouch. Refer to the expiration date for stability. Do not freeze.
Span Biotech Ltd. is a research based company for rapid tests, with strong support from National Key Laboratory of Technology Projects of 10th and 11th Five-Year Plan and Faculty of Life Sciences of HuBei University. SpanBio also housed a R&D team that is developing gene recombination, cell cultivation and protein purification techniques. SpanBio pays strict attention on rapid tests for human being, animal diseases and food safety detection. It provides a number of customized services to professional distributors and partnering affiliates with excellent quality, competitive prices and super service.
Our mission:
Rebecca Yan
Contact Person: Ms. Anna Lee
Tel: +86-755-89589611
Fax: 86-755-89580096